Xencor reported third quarter 2026 net income of US$39.44 million and positive earnings per share, while year to date results still show a net loss of US$111.21 million, underscoring the financial weight of its ongoing research programs. Initial Phase 1b data for subcutaneous plamotamab in rheumatoid arthritis, released at ACR 2026, showed deep B-cell depletion linked with reductions in disease activity. This highlights how Xencor's bispecific platform could extend beyond oncology into...
Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.
2026-10-27. The following slide deck was published by Xencor, Inc.
Shares hit a nearly four-year high on positive results in kidney cancer.
Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.
Xencor (XNCR) has an average rating of overweight and mean price target of $31.25, according to anal
Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.
PASADENA, Calif., September 02, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.
This is the newest page. Registered accounts read further back.